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Radiation oncology, a major treatment modality in the care of patients
with malignant disease, is a technology- and computer-intensive medical
specialty. As such, it should lend itself ideally to data science methods,
where computer science, statistics, and clinical knowledge are combined to
advance state-of-the-art care. Nevertheless, data science methods in radia-
tion oncology research are still in their infancy and successful applications
leading to improved patient care remain scarce. Here, we discuss data
interoperability issues within and across organizational boundaries that
hamper the introduction of big data and data science techniques in radia-
tion oncology. At the semantic level, creating common underlying models
and codification of the data, including the use of data elements with stan-
dardized definitions, an ontology, remains a work in progress. Method-
ological issues in data science and in the use of large population-based
health data registries are identified. We show that data science methods
and big data cannot replace randomized clinical trials in comparative effec-
tiveness research by reviewing a series of instances where the outcomes of
big data analyses and randomized trials are at odds. We also discuss the
modern wave of machine learning and artificial intelligence as represented
by deep learning and convolutional neural networks. Finally, we identify
promising research avenues and remain optimistic that the data sources in
radiation oncology can be linked to yield important insights in the near
future. We argue that data science will be a valuable complement to, but
not a replacement of, the traditional hypothesis-driven translational
research chain and the randomized clinical trials that form the backbone
of evidence-based medicine.
1. Introduction
Data science is a multidisciplinary field that uses scien-
tific methods, processes, algorithms, and systems to
extract knowledge and insights from structured and
unstructured data (Wikipedia, 2019). Data science is
emerging as a new paradigm in the biomedical
sciences, distinct from conventional theoretical and
empirical science. In this new paradigm, patterns
detected in large sets of clinical data provide a means
to understand the nature of disease and its response to
therapy, either alone or by representing a bedside-to-
bench inverse translation, in which hypotheses are
derived from clinical outcome data and then later
studied in detail in the laboratory or tested in con-
trolled clinical trials.
Abbreviations
API, application programming interface; DL, deep learning; EHR, electronic health record; PRO, patient-reported outcome; R&V, electronic
record-and-verify systems; RGC, Radiogenomics Consortium; SNP, single nucleotide polymorphism.
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A successful data science project should combine
computer science, statistical knowledge, and domain
knowledge from the field of interest.
Radiotherapy is a mainstay in modern anticancer
therapy and is indicated in more than half of cancer
patients at some point during disease management
(Lievens and Grau, 2012). Modern radiotherapy is a
computer-intensive and technology-heavy discipline
with regulatory requirements for documenting and ver-
ifying radiotherapy exposure and should therefore be
well suited for data science advances.
In the present review, we focus on data science in
radiation oncology, as defined by the combination of
data analytics and big data sources with the ultimate
aim of gaining insights into improved therapy for
future cancer patients. The data science paradigm can
be contrasted with the translational research chain
paradigm (Fig. 1), and in this review, we define data
science as shown in Fig. 1. It should be mentioned
that the workflow in radiation oncology is complex
and involves many tasks that are likely to be success-
fully automated or at least partly supported by tools
developed using machine learning techniques (Meyer
et al., 2018; Thompson et al., 2018). Although there
are some promising parallels between these efforts and
the data science approach discussed here, it is beyond
the scope of this review to cover the automation of
radiation treatment planning and delivery in any
detail.
Data science is, in many ways, a compelling concept
in the field of radiation oncology. First and foremost,
a data science approach seeks to analyze data on
human patients treated as part of clinical routine. Pre-
clinical tumor models show many important biological
differences to spontaneous tumors in humans. With
current advances in the understanding of the impor-
tance of host–disease interactions (Hanahan and Wein-
berg, 2011), in particular with the rise of immuno-
oncology, including immunotherapy–radiotherapy
combinations, the limitations of relying mainly on
in vitro assays and small-animal models to develop
new therapies are clear. Secondly, adverse events of
radiation therapy depend not only on the detailed
deposition of dose in time and space but also on
patient-level comorbidities, comedications, and patient
age (Bentzen, 2006). These are cofactors that are diffi-
cult to represent adequately in preclinical models.
Also, the analysis of routine clinical data is a promis-
ing complement. Indeed, we have seen examples where
human outcome data analysis has been used to
describe the detrimental impact of radiotherapy on the
immune system (Shiraishi et al., 2018; Terrones-Cam-
pos et al., 2019; van Rossum et al., 2020). Such
findings might may serve as an important context for
preclinical studies that aim to explore the beneficial
effect of radiation for immune therapy (Durante and
Formenti, 2019; Formenti and Demaria, 2013).
Thirdly, although the controlled clinical trial is very
likely to remain as the gold standard in evidence-based
radiation oncology (Bentzen, 1998; Bentzen and Yar-
nold, 2014), there are numerous types of questions that
cannot easily be subjected to clinical trial methodol-
ogy. Big data from population-level registries are
increasingly emerging as an important complement to
trial outcomes, as discussed further below. In the case
of radiation oncology, however, the big data are
unfortunately often not all that big.
In this review, we discuss the data sources involved
in radiation oncology data science, the methodological
hurdles to consider when using big data sources, and
potential solutions and promising future research ave-
nues. We finish with an important discussion of the
clinical utility of the knowledge obtained from data
science in radiation oncology.
2. Data sources and missing links in
radiation oncology
Large databases of treatment and outcome data have
long been available for healthcare providers and
researchers in multiple countries and regions across
the globe. Databases provide essential reimbursement
mechanisms for healthcare providers across public and
insurance-based systems alike. Furthermore, most
developed countries have national cancer registries
with mandatory reporting of incident cases.
At the hospital level, electronic health records
(EHRs) have long been in routine use in developed
countries, and few will disagree that EHRs will expand
their future role as an integral part of the hospital data
infrastructure. Finally, focusing on the radiotherapy
providers, electronic record-and-verify (R&V) systems
are mandatory for documenting detailed radiation
exposure and for improving patient safety. Detailed
exposure data for all patients are stored and must be
retrievable for clinical use in the common event of a
future indication for re-irradiation. These different
data sources, together with their key strengths and
weaknesses, are shown in Fig. 2.
We note a substantial challenge in radiotherapy data
science: the immediate loss of detailed radiotherapy
exposure data when moving data from the departmen-
tal R&V database to other data sources. Hospital
EHRs will typically carry information on prescription
dose, time, and delivered number of fractions, but not
the 3D dose distribution data available from R&V
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records. When moving beyond the hospital to claims-
based registries or tumor registries, radiotherapy is
often only recorded as a one-bit yes/no item, which,
with few exceptions, preclude meaningful inference
with regard to the optimal use of radiotherapy. Con-
versely, the R&V databases lack the crucial long-term
outcome data from the larger systems (Fig. 3) and will
often be limited in terms of the number of individuals
treated. Even when patient-level links exist between
these databases, developing an ontology for defining
structures and for reporting doses for R&V records,
and for defining specific long-term outcomes on the
registry side, remains work in progress.
Powerful examples of the value of establishing a
widely adopted ontology include the TNM classifica-
tion for staging of cancer, developed between 1943
and 1952 by P. Denoix at the Institute Gustave-
Roussy. This ontology was subsequently adopted by
the Union for International Cancer Control (UICC),
the International Federation of Gynecology and
Obstetrics (FIGO), and the American Joint Committee
for Cancer (AJCC) (UICC, 2017). Another example is
the development of the Common Terminology Criteria
for Adverse Events (CTCAE), which has been widely
adopted by many single or multimodality cancer stud-
ies (Trotti et al., 2003). In radiation oncology, there
have also been commendable efforts to standardize
organ delineation for radiation therapy planning and
the corresponding nomenclature used in routine clini-
cal care (Duane et al., 2017; Landberg et al., 2016;
Offersen et al., 2015).
Nevertheless, ensuring the interoperability of data-
bases requires us to do more. We need to define a set
of minimum data elements to record radiation modal-
ity and delivery technique, which would be an impor-
tant step forward (Hayman et al., 2019). However, the
effort needed to achieve a full, meaningful annotation
of complex 3D imaging and exposure data is substan-
tial. It should be recognized that manual annotations
are often inconsistent even within a department and
that they are generally restricted to the normal struc-
tures necessary for treating the patient in question; fur-
ther details needed for research cannot be expected to
be reliably annotated in clinical routine databases.
Having said that, the retrospective estimation of
dosimetry might be possible in the absence of 3D
Basic science In vitro study Pre-clinical animal models Phase I trial Phase III trial Adoption/population
Adoption/population Machine learning
statistical modeling Basic science
Trial
Laboratory
Data science
Translational research
Data aggregation
Fig. 1. The translational research chain versus the data science approach.
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dosimetry data in selected cases: For example, cardiac
exposure after breast and lymphoma treatment can be
reasonably reliably quantified from 2D portal images
or treatment descriptors in historical series (Darby
et al., 2013; Maraldo et al., 2015; van Nimwegen
et al., 2017). Modern radiotherapy planning is becom-
ing increasingly individualized, however, and therefore,
such retrospective dosimetry will, in most cases, be
unreliable with current radiotherapy (Maraldo et al.,
2012). The studies of cardiac exposure demonstrate
another main strength of data science: the potential
ability to study relatively rare, high-grade toxicity end-
points of high clinical relevance, such as major coro-
nary events (Darby et al., 2013). Most institutional
series will not have enough power to resolve any rele-
vant exposure–risk relationships for high-grade toxicity
events. Consequently, low-grade clinical endpoints
(such as low-grade radiation pneumonitis for lung
exposure; Marks et al., 2010a; Marks et al., 2010b)
often form the basis for recommended dose con-
straints, even when the disease itself has a dismal prog-
nosis.
As an alternative to using the registries mentioned
here, multiple institutions have successfully combined
data in population-based studies (Thorsen et al., 2016)
in which the numbers of cases reach several thousands,
but in which dosimetry data remain limited. Finally,
the concept of federated learning has been proposed
and demonstrated as a means by which to combine
insights from institutional series without the logistical
and legal complexities of sharing patient data
(Defraene et al., 2019; Jochems et al., 2017). However,
the numbers of patients and the dosimetric granularity
offered by current published examples of federated
learning remain limited, as shown in Fig. 3. We now
leave the data source discussion to focus on challeng-
ing aspects of the data analysis itself.
3. Applying data science to radiation
oncology: The methodological
challenges
Here, we discuss the methodological challenges of
applying data science to radiation oncology. It should
be emphasized that the covariates, as well as the end-
points that are analyzed, should be defined by clinical
relevance or scientific interest and not by availability.
When analyzing and publishing the data science mate-
rial, it is relevant to keep some terms and concepts in
mind. The safest route to appease a peer reviewer is to
Population based
Tumor stage info
All modalities
Only mortality as outcome
RT yes/no at best
Missing clinical data
Limited RT data
Long-term data missing
Missing ontology
Lab data, medications, procedures
Image data
Written charts
RT yes/no at best
No tumor details
Baseline lab data missing
Long term data
Detailed outcome (procedures)
Ontology (ICD10)
3D RT exposure
Tumor delineations
Images: baseline, during RT
Missing other treatment data
No outcome data
Limited ontology
Data loss
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Fig. 2. Key sources of data and points of radiation data loss. From lower left and counterclockwise, radiation dose plan banks are currently
available in all modern institutions as record-and-verify systems that contain image data and 3D radiation dose exposure, but no follow-up
data. Hospital-based EHR systems contain more detail on other treatments, but do not contain detailed, granular radiotherapy data; such
data are often reduced to prescription dose/fractionation. Radiotherapy data are further lost when these data are moved to large claims-
based registries or tumor registries, where data on various aspects of long-term outcome are available. Red boxes: examples of main
shortcomings of data source. Green boxes: examples of main strengths.
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argue that the objective of a data science publication is
to elucidate associations in data. A limitation of this
approach, however, is that the presence of associations
rarely has any clinical relevance. The next step would
be to perform prediction of outcome. Predictive mod-
els rely on one or more covariates that together give
an (ideally) robust assessment of the probability of a
given endpoint (Collins et al., 2014, 2015). Note that
the covariates need not be causally related to the end-
point in question to provide an accurate outcome pre-
diction. The downside of predictive modeling without
causal content is that the use of further refined radio-
therapy to modify a dose distribution-related covariate
might fail to provide the expected clinical benefit if
other associations are broken, for example, when mov-
ing from photon to proton therapy. Causal relation-
ships are generally preferable to both association
studies and predictions without causal inference, but
inference methods rely on avoiding bias. Here, the
most robust method is the randomized controlled trial,
but other methods exist where randomization is not
feasible (Pearl, 2009).
Although causal inference is challenging, and prone
to residual bias and confounding even when exercising
the best possible care (cf. Fig. 4), such methods are
likely to be more efficient when combined with
improved, prospective outcome reporting, across a
change of treatments (e.g., when moving from photon
to proton therapy). Such prospective data registration
programs are in place at a few leading institutions,
with the Dutch-coordinated effort in head-and-neck
cancer radiotherapy across modalities and institutions
as a prime example (Verdonck-de Leeuw et al., 2019).
Patient-reported outcomes (PROs) are also of great
interest in relation to toxicity assessments, and some
data suggest that they can improve routine clinical
care (Basch et al., 2017). More research is needed,
however, into the relationship that exists between
PROs, and physician-assessed and analytical toxicity
endpoints.
In order to be relevant and acceptable to radiation
oncologists, predictive models must account for
already well-established risk factors. In terms of the
risk of toxicity, several clinical covariates have already
been established (Appelt et al., 2014; Thor et al., 2019;
Vogelius and Bentzen, 2012), and should be accounted
for in the modeling. When it comes to disease-control
endpoints, adjustment for disease stage is clearly neces-
sary (and often available in tumor registries), but more
detailed knowledge of disease burden and other prog-
nostic factors might be important as well, in order to
test the added utility of novel prognostic assays. For
example, tumor volume and HPV status have been
shown to provide more robust predictors of survival
than radiomics features in head-and-neck cancer (Ger
et al., 2019). Similar examples exist of clinical factors
that confound image-derived features in lung cancer
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Fig. 3. Schematic illustration of loss of granularity of radiotherapy
data when moving from single institutional series to the largest of
available datasets. This graph provides a schematic illustration of the
level of radiotherapy data granularity versus sample sizes across
selected published studies and available databases in the United
States as examples. QUANTEC (Marks et al., 2010a) is an example
of a federated learning model that aims to bridge institutional series
(Defraene et al., 2019). Also shown is a population-based series of
breast cancer patients without detailed dosimetry, but with
information available about whether internal mammary nodes were
included in the radiotherapy target (Thorsen et al., 2016). The graph
also shows the number of patients in randomized trials of external
beam radiotherapy (EBRT) for prostate cancer (Vogelius and
Bentzen, 2018; Widmark et al., 2019), the number of patients in
Radiation Therapy Oncology Group (RTOG) trial databases (personal
communication), and the number of breast cancer patients in the
National Cancer Database (NCDB) and Medicare. Where long-term
outcomes are available in the large series (to the right), radiotherapy
information is often reduced to one bit of information (radiotherapy
given or not) in these studies (McGale et al., 2016). Abbreviations:
QUANTEC: Quantitative Analyses of Normal tissue Effects in the
Clinic. RT, radiotherapy; RCT, randomized controlled trial.
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(Davey et al., 2020). An important general discussion
of such problems can be found in Welch et al. (2019).
Some authors have argued in favor of registry-based
studies by highlighting the many obstacles that are
encountered when designing and conducting large, ran-
domized controlled trials (Quon et al., 2019). The
problem remains, however, that even after adjusting
for available known covariates, hidden biases might
still exist. This is exactly why the randomized con-
trolled trial remains the gold standard of generating
medical evidence in comparative effectiveness research.
This does not preclude, however, mathematical model-
ing and data science methods as a component of evi-
dence-based medicine.
4. Mathematical modeling and
evidence-based medicine
Mathematical modeling is an attractive method for
data-driven inference, where evidence from random-
ized trials is not available, trials are not feasible, or as
a tool to describe heterogeneity in treatment effect.
But how do we build confidence in a predictive model
that supports clinical decisions? A key element to this
end is external validation, that is, a quantitative assess-
ment of a model’s performance in an independent
dataset. There is a rich statistical literature on the vali-
dation of models (Collins et al., 2014, 2015). However,
the term validation itself is not consistently defined
(Altman and Royston, 2000), especially in radiation
oncology, where exposure variables are often corre-
lated. Still, most validation studies tend to conclude
that the model tested is indeed valid! But there is no
consensus among radiation oncology modelers as to
what this exactly means. And validation is only mean-
ingful within a carefully specified domain; models are
most often not generalizable across domains. For
example, a dose–volume–response model developed
from photon therapy outcomes in adults may have
been ‘validated’ in a similar setting but may not per-
form well in a cohort of patients treated with proton
therapy, or in a population of, say, pediatric patients.
Using the literature, we have compared data science
approaches against the gold standard of the random-
ized controlled trial in some radiotherapy-relevant
cases (Ang et al., 2014; McGale et al., 2016; Pignon
et al., 2009; Zandberg et al., 2018), where the effect
size of an intervention has been estimated using both
methods (Fig. 4). In many cases, the randomized con-
trolled trial and registry-based effect estimates do not
fall on the diagonal line of agreement, even when con-
sidering their confidence intervals. Or they are in direct
contradiction (as shown by the gray zones in Fig. 4).
The meta-analysis by Pignon et al. (2009) shows that
the coordinated synthesis of trial outcomes can yield
statistical power that is comparable to that of registry
analysis but without the associated risk of bias. It is
remarkable that the confidence intervals of well-con-
ducted meta-analyses are often comparable to those of
registry studies, despite fewer patients (Pignon et al.,
2009). This is an indication that statistical power in
registry studies is not limited by sampling variation
alone, but by an overdispersion of effect sizes between
individuals in the data, resulting from heterogeneity of
treatment effects. It should be emphasized that for reg-
istry studies, it is the management of bias/confounding
that dominates over statistical sampling uncertainty.
P-values, which were developed to compare small sam-
ple sizes, often look impressive at face value in registry
studies, but should largely be ignored because bias/
confounding is the real concern (cf. Fig. 4). Effect sizes
with confidence intervals are much more informative,
but even these should be tempered by a careful analy-
sis of possible bias.
The limitations of data science should thus be recog-
nized in comparative effectiveness research. However,
data science is an important and very relevant supple-
ment to the paradigm of translational research, in par-
ticular for questions that are not amenable to being
investigated by randomized controlled trials. This
includes the previously mentioned example of a dose–
response relationship for cardiotoxicity. In the next
section, we discuss the dominant methodological devel-
opment in data science, artificial intelligence, or, more
precisely, deep learning (DL) methods.
5. Artificial intelligence: Deep
learning
Machine learning is a branch of artificial intelligence, in
which a mathematical model is built based on a sample
dataset, known as the ‘training dataset’. This field of
data science is being revolutionized by DL methods, a
term that is typically associated with the training of mul-
tiple-layered/deep neural networks. DL techniques are
increasingly being explored in radiotherapy, for pur-
poses such as treatment planning, setup, verification,
adaptation, or follow-up in clinics and in research
(Meyer et al., 2018; Sahiner et al., 2019). In contrast to
methods that combine selected and designed features
and classifiers, DL utilizes end-to-end representation
learning, in which features and their combinations are
learned at multiple hierarchies jointly to solve a particu-
lar prediction task directly from data. This is one of the
reasons for this approach’s success. DL most often
involves learning from suitably sampled training data
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with ground-truth annotation provided by human
experts or observed clinical outcome, so-called super-
vised learning. Less frequent applications involve
semisupervised and even unsupervised learning, in
which learning is done by finding inherent structures in
the data with limited or no ground truth provided (see
Table 1 for a glossary of terms).
Employed DL models can easily fit to both relevant
and spurious signals and even to random noise in the
training data (Zhang et al., 2016), and the perfor-
mance or ability to generalize to unseen data is there-
fore the relevant measure of success. The
generalization error of a DL model, given a problem
and training data, is something that must be empiri-
cally estimated, and occasional failures should be
expected and recognized as an inherent property of the
DL approach. As DL methods become an integral
part of clinical workflow and research, these risks must
be properly assessed. It is not enough to assess a DL
model’s performance on measures, such as average
similarity of segmentations and reconstructed images,
with ground truths that are often clinically irrelevant.
This is because DL methods are surprisingly good at
recognizing and replicating even complex signals that
often appear in the training data, while potentially fail-
ing to recognize obvious but rare signals that occur
clinically (Meyer et al., 2018). Estimates of prediction
uncertainty in DL models could be used to raise warn-
ing flags in such cases. Such estimate prediction tech-
niques include Monte Carlo dropout (Kendall and
Gal, 2017), model ensembles (Lakshminarayanan
et al., 2017), and variational autoencoders (Hu et al.,
2019; Kohl et al., 2018), which function by allowing
many different predictions to be generated for each
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published effect-size estimates from randomized controlled trials (x-axis) and registry-based analyses (y-axis). Concordant effect sizes are
indicated by the black identity line. We see examples of registry-based studies over- and underestimating effects, as well as being relatively
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data point. Under the critical assumption that the
training set is representative of the underlying true dis-
tributions, such methods should be able to convey the
variation of predictions to the end user, whether they
are a scientist or clinician. However, more work is
needed to bridge this critical gap of conveying uncer-
tainty information when using these novel modeling
approaches.
A related critique about DL methods is the ‘black-
box’ nature of its output, which can result in a lack of
transparency or even interpretability (Vollmer et al.,
2020). Because DL methods consist of deep hierarchies
of nonlinear functions, whose many parameters are
entirely learned from data, understanding their inner
workings and predictions is not straightforward. This
contrasts with conventional regression models that
base their predictions on handcrafted features, and on
the statistical significance and the associated effect size
(e.g., relative risk or hazard ratio) for each feature,
which can be reported to understand the drivers of the
model. Understanding why and how DL models work
is an active research area, as is conveying such
Table 1. Glossary of data science terms.
Application programming interface
(API)
Communication protocol that allows external communication with software or server. In this field, APIs
allow researchers to write code (scripts) to query radiotherapy databases to extract features from
(large numbers of) individual patients’ scan or dosimetry data
Artificial neural networks (ANNs) An ANN is a network of artificial neurons, connected such that output from a given neuron forms the
input to one or more neurons in the next ‘layer’. Passing input data through many successive such
layers allows for complex transformations, that is, complex mathematical functions that link a set of
inputs to a specific output
Artificial neuron The artificial neuron is the basic building block of an ANN. It is a mathematical function that takes
multiple real-valued inputs, each of which is multiplied by a weight. These weighted inputs are then
summed and put into a so-called activation function that outputs a real value. The activation function
is typically a nonlinear function, for example, a sigmoid function
Deep learning (DL) A type of learning that uses multiple ANN layers to progressively extract higher level features from the
raw input
Federated learning (a.k.a.,
distributed learning)
This approach entails training a model simultaneously on several datasets that reside on different
servers while communicating model data (such as goodness-of-fit data and regression coefficients)
rather than exchanging the data itself
Generalization error Generalization errors are calculated by metrics that quantify the amount of error a prediction algorithm
makes on a set of previously unseen data
High-dimensionality datasets This is a general term used to describe datasets that contain large numbers of features per patient,
including genomic data and image features
Machine learning (ML) The study of how computers learn from data to solve problems. ML is also used to refer to algorithms
or systems that learn from data how to solve a task, as opposed to being explicitly programmed how
to do so
Multiple-layered network/deep
neural networks
These are neural networks that consist of many layers of neurons between the input and output, such
that the output of one layer becomes input for the next
Ontology Representation, formal naming, and definition of the data in a field of research, examples are tumor
characteristics (e.g., UICC staging), organ delineation/naming, dose descriptors, and disease/
procedural codes
Record-and-verify databases Databases that were originally invented to document treatments and reduce risk of errors, and that
have evolved into complete information systems that contain image data, planned dose matrices, and
detailed delivery data. They usually have some sort of application programming interface
Semisupervised learning Machine learning from input data, where only a subset of input data is paired with output data, that is,
an approach that mixes supervised and unsupervised learning
Single-layer model This term describes conventional regression models that could be seen to provide a ‘single layer’: In
these models, a single mathematical descriptor (e.g., logistic function or Cox model) connects input
data to outcome prediction. It is used for illustration here, but it is not an often-used term
Supervised learning The task of learning a function that maps an input to an output, based on example input–output pairs.
Regression models are examples of this approach
Tall datasets These are ‘Big data’ datasets where the number of cases (individuals, patients) is much larger than the
number of features per case. Examples are population-based cancer registries or claims databases
Unsupervised learning This approach finds patterns in datasets without preexisting labels, that is, based solely on the
structure of the input data, which is also known as self-organization. Hierarchical clustering is an
example of such a method
Wide datasets ‘Big data’ datasets, in which the number of features (data items) per case is much larger than the
number of cases. Examples include data from genomics or proteomics or from medical imaging
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information to the end user (Gilpin et al., 2018). For
instance, possible insights into the inner workings of
trained DL models can be gained by perturbing inputs
and investigating the possible consequences, or by gen-
erating heat maps of the importance of a particular
part of the input for a given prediction (Ancona et al.,
2017; Sahiner et al., 2019).
The major factor that limits the performance of DL
methods in medicine is the lack of good-quality refer-
ence data to learn from, thus emphasizing the impor-
tance of bridging the gaps in the data sources
discussed earlier in the review. The performance of DL
models grows with the amount of data in the training
set, and although the performance of individual DL
models can become saturated after a certain amount
of data is included, further improvements can typically
be made by extending model architectures (Hestness
et al., 2017; Sun et al., 2017). Making public datasets
that comprise protected health information is compli-
cated by patient privacy concerns and laws, but has
the potential to contribute enormously to advancing
the field. The website grand-challenge.org hosts a large
number of challenges and datasets in medical imaging,
including the StructSeg2019 segmentation for radio-
therapy planning challenge 2019 (Structseg, 2019).
However, there is still a limited number of challenges
and datasets for radiotherapy applications available.
6. Promising solutions and leaps
forward
It is clear, that data loss is a primary obstacle to
applying data science to radiation oncology, in partic-
ular the loss of detailed information about radiation
exposure and image data when linking from dose plan
to outcome registries. However, promising tools exist
to overcome this data loss.
For instance, modern radiotherapy record-and-verify
systems now provide users with relatively accessible
interfaces to enable them to interact with data on a
database level, using a so-called application program-
ming interface (API). APIs are emerging as automa-
tion procedures, and they enable the reporting of
dose–volume data for available annotated body
regions in the dose planning systems (Cai et al., 2019;
Cardan et al., 2019). APIs have also been used to link
lung exposure to vital status registries (Stervik et al.,
2020). While these methods are still limited to struc-
tures delineated at the time of treatment planning and
stored in the database, it is still a substantial leap for-
ward from datasets that record dates, times, and pre-
scription dose, but not dose distribution (Rubinstein
and Warner, 2018).
Another approach to improve the interoperability of
distinct datasets is the establishment of large consortia
of collaborators. One example is the Early Breast Can-
cer Trialists’ Collaborative Group (EBCTCG), which
combines randomized trials data to achieve statistical
power comparable to registry studies (Fig. 4). Another
successful example is the Radiogenomics Consortium
(RGC). Radiogenomics is the scientific study of the
link between early or late radiation toxicity and com-
mon genetic variations, such as single nucleotide poly-
morphisms (SNPs). SNPs occur on average once in
every 1000 nucleotides in the human genome, which
means that there are roughly 4–5 million SNPs in an
individual patient’s genome. Due to the high dimen-
sionality of SNP datasets, the early literature on SNP
predisposing for radiation toxicity was dominated by
false-positive SNPs that were not validated in indepen-
dent data series (Barnett et al., 2012a). This issue,
combined with the inherently large number of covari-
ates that affect the phenotypic presentation and the
relatively low prevalence of many single-nucleotide
variants of potential interest, means that this research
field requires relatively large sample sizes to achieve
sufficient statistical power to detect clinically relevant
effect sizes (Barnett et al., 2012a). To this end, RGC
was established in 2009 (West and Rosenstein, 2010).
It consists of a large volunteer research network,
which currently comprises 222 members in 33 coun-
tries across 133 institutions. The RGC has successfully
identified SNPs involved in radiation toxicity
(Andreassen et al., 2016; Kerns et al., 2019), which are
of potential value in guiding therapy decisions in indi-
vidual patients (Bergom et al., 2019).
Federated learning is another collaborative
approach but one that removes the need to share pro-
tected health information. However, current publica-
tions from federated learning collaborations are
limited to sample sizes that are smaller than the most
prominent consortia (cf. Fig. 3).
Federated learning, consortia, or the automated
linkage of record-and-verify databases to registries all
suffer from a limited ontology of organ structure
delineations, as well as limited ontology for procedures
and endpoints. Adjusting for between-data-series vari-
ation is often an important contribution of consortia.
For example, RGC has contributed to the field’s
methodology by providing methods to standardize tox-
icity scores between data series (Barnett et al., 2012b).
The limited availability of organ delineations on rou-
tinely treated patients is a challenge that remains, but
automated delineation approaches are being actively
pursued by both commercial and academic researchers
as a way to counteract the continuously increasing
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burden of substructure delineation in clinical practice
(Zhu et al., 2019). These methods are expected to
improve in performance in coming years, and can also
be used to increase the granularity of organ exposure
in all of the above settings. In addition, structure
delineation might come to include much more detailed
substructures beyond those that are of current rele-
vance for guideline-driven radiation dose planning.
Figure 5 shows an example of automated airway and
vessel annotation on a routine scan from record-and-
verify database, which clearly exceeds the detail that
could ever be achieved on substantial patient numbers
with manual segmentation.
It should be emphasized that despite the difficulties
associated with data linkage and interpretation, a fun-
damental truth is that the data are there and the data
are accessible. We are no longer limited by manual
tape switching or by the need to burn and send
DVD’s, as we were just 10 years ago. We are in an era
where it is becoming realistic to perform large-scale
analysis of detailed exposure data across many
institutions. Despite the necessary efforts to secure
patient confidentiality and legal collaboration agree-
ments, there are good reasons to be optimistic about
the ability to harness data science in radiation oncol-
ogy.
7. Towards clinical utility
Turning to the discussion of clinical utility of data
science findings (Liu et al., 2019), it should be empha-
sized that the key word in data science is science rather
than data. The success of data science in radiation
oncology will ultimately be measured by the clinical
utility of the AI tools that are developed or by the
novel scientific insights that are uncovered by using
such methods, rather than by the simple ability to gen-
erate yet another prognostic model or by referring to
the amount of data analyzed.
To that end, the methodological challenges must be
overcome, and defining analyses and endpoints by
availability must be superseded by choosing covariates
Fig. 5. A DL algorithm to analyze radiation exposure in routine clinical setting. Output from a DL algorithm in the form of a 3D U-Net
architecture (Ronneberger et al., 2015). The algorithm was trained on a dataset of manual annotations of lung substructures (vessels and
airways). Subsequently, the DL algorithm performed annotations on a previously unseen routine, planning CT scan from a record-and-verify
system yielding the airway and vessel annotations in green shades depicted on the left. Right: The annotated CT scan is overlaid with a 3D
dose color wash to show the potential of automating access to detailed radiotherapy exposure data, which may subsequently be connected
to outcome data from the larger registries. Note that some of the smaller vessels are exaggerated in size due to partial volume effects.
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and endpoints based on clinical relevance and insight.
There is an urgent need for cancer-specific endpoints
rather than overall survival, which is used in even the
best current tumor registries.
Uncertainty, bias and generalizability should be
assessed critically to enable the end user clinician to
judge the validity of the model. This is not a new
insight (Wyatt and Altman, 1995), but it becomes even
more important in the era of neural networks and big
data science. The treating physician must fulfill the
role of a ‘learned intermediary’ when using decision
aids generated by data science and in order to fulfill
that role the predictive model must have face validity
and provide adequate descriptions of uncertainty. Clin-
ical credibility is certainly still relevant. This is also an
educational challenge: Radiation oncologists must be
taught how to read, understand, and critically appraise
papers that report data science results.
There are two examples of clinically relevant prob-
lems that can only be solved by big datasets and where
data science is particularly promising: re-irradiation and
detailed pattern-of-failure analysis. The retreatment of
patients is a very common challenge in radiation oncol-
ogy, yet our knowledge of organ tolerance is very lim-
ited. This is a complex problem where the intensity of
the first treatment, the time interval from the first treat-
ment, and the full time line of other anticancer medica-
tions are all expected to impact the risk of adverse
events. Similarly, our knowledge of the detailed pattern
of failure after primary radiation is currently limited to
small, opportunistic series that fail to reflect the fre-
quency of cancer recurrence after radiotherapy as a clin-
ical problem (Chao et al., 2003; Due et al., 2014;
Nygard et al., 2018). This is a major limiting factor in
harnessing the recent technological developments in
radiation oncology to provide a dose-painting approach
to radiotherapy, as envisioned decades ago by Ling
et al. (2000) and Bentzen (2005). Clearly, modern radio-
therapy equipment has the ability to meet these needs,
but the biological knowledge has to come from data
science, and the resulting data-driven hypotheses for
treatment improvements will subsequently need com-
parative effectiveness testing in controlled clinical trials.
8. Conclusion
In conclusion, data science has an important role to
play in radiation oncology and we are currently seeing
just the first wave of that influence. It should be
remembered, however, that data science should be
multidisciplinary, and as such, it should involve statis-
tical capabilities, and computational and domain
knowledge from clinical radiation oncology.
Clearly, the translational research chain has limita-
tions that are well described in the literature, including
the reproducibility crisis and, equally important but
less appreciated, the risk of falsely rejecting a good
target prior to entering the human testing phase (Bau-
mann et al., 2001; Begley and Ellis, 2012). The addi-
tion of big data and data science will supplement, but
not replace, the translational research chain. For data
science to achieve its potential in radiation oncology,
however, several breakthroughs are needed to over-
come the limitations mentioned above.
In our view, as shown in Fig. 1, data science should
complement translational science and traditional meth-
ods should be used to verify conclusions whenever
possible. Data science methods applied to large
curated datasets linking high-dimensionality biomarker
data with clinical outcome data have the potential to
provide tangible benefits to our future patients.
Domain knowledge, however, is a key ingredient
needed to harness the power of these methods.
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